Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic Acid and Karenitecin for Metastatic Malignant Melanoma
NCT00358319Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of karenitecin, valproic acid in Malignant Melanoma (MM), sponsored by Moffitt Cancer Center. Started Mar 2005; status: terminated.
02
Drugs
karenitecinvalproic acid
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00358319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358319.